Early PCR Confirmation and Fewer Visit as the Key to Improving HCV Treatment Rates in a Predominantly African American GI Clinic

Background/Objectives: The approval of direct acting antiviral (DAA) therapy for hepatitis C (HCV) resulted in a highly effective oral treatment for patients. The primary objective of this study was to compare patients who were not treated to patients who were treated. Identifying potential reasons for the failure to treat can provide a pathway to interventions using evidence-based data. Methods: The electronic medical records in an urban predominately African American (AA) population were searched for all patients with HCV seen at least once in a GI or ID clinic 2019. Data collected included demographics, treatment visits, laboratory, insurance, and ZIP codes for median income. Results: Of the 441 patients who were not yet treated at the first 2019 visit, only 43% were treated by July 2020. Insurance and median income were not factors in failure to treat. Patients with an average of 4 visits were more likely to be treated than those with 2 or less thus confirming that failure to follow up was a significant factor for patient treatment (42% vs 8% p